Prof Michael Barry, the clinical director of the National Centre for Pharmacoeconomics, stated that the biggest challenge in the medicines area will be determining the availability of new obesity treatments to patients. One such treatment, tirzepatide, also known as Mounjaro, is set to undergo a health technology assessment to decide if it should be made accessible to patients in Ireland. This assessment will determine the circumstances in which the treatment should be available. Additionally, another obesity treatment, Wegovy, is currently being evaluated. The availability of these new treatments for obesity will be a significant issue in the healthcare sector.
Source link
Determining reimbursement for new weight-loss treatments will be ‘the biggest challenge in the medicines area, bar none’ – NCPE head
